Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
79 hedge funds and large institutions have $121M invested in Marinus Pharmaceuticals, Inc in 2019 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 26 increasing their positions, 17 reducing their positions, and 8 closing their positions.
188% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 8
152% more capital invested
Capital invested by funds: $48.1M → $121M (+$73M)
53% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 17
23% more funds holding
Funds holding: 64 → 79 (+15)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
57% less call options, than puts
Call options by funds: $605K | Put options by funds: $1.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$8.7M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.73M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$6.73M |
| 4 |
LPC
Lion Point Capital
New York
|
+$4.1M |
| 5 |
VMI
VHCP Management III
New York
|
+$3.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$3.74M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$1.18M |
| 3 |
6CM
683 Capital Management
New York
|
-$245K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$124K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$55.1K |
MRNS Hedge Fund Activity: Q4 2019 in Review
79 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q4 2019, worth a combined $121M — up 152% from $48.1M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new MRNS positions and 8 closed out — a net gain of 15 holders — while 26 added to existing stakes and 17 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $8.7M. The largest seller was Franklin Resources, exiting entirely with an estimated $3.74M sold.
- 79 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q4 2019, up from 64 in Q3 2019.
- Funds reported $121M of Marinus Pharmaceuticals, Inc stock for Q4 2019, up 152% quarter-over-quarter.
- 23 funds opened new Marinus Pharmaceuticals, Inc positions in Q4 2019 and 8 closed out, a net change of +15 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q4 2019 was Avoro Capital Advisors, an estimated $8.7M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q4 2019 was Franklin Resources, an estimated $3.74M sold.
Based on aggregated 13F filings for Q4 2019.